Edward White

InflaRx N.V. (NASDAQ: IFRX) shares are rallying hard Thursday. Here's why.  What Happened: German biopharma InflaRx, which focuses on developing therapies for autoimmune and inflammatory diseases, announced positive data Wednesday from the third cohort of patients in the Phase 2a study...

H.C. Wainwright analysts remain bullish on ChemoCentryx, Inc. (NASDAQ: CCXI) following an amended new drug application for avacopan. The ChemoCentryx Analyst: Edward White reaffirmed a  Buy rating on shares of ChemoCentryx, Inc. with a $28 price target.  The ChemoCentryx Takeaways:...

The advancements with COVID-19 vaccines of Pfizer Inc. (NYSE: PFE), Moderna Inc. (NASDAQ: MRNA), and AstraZeneca Inc. (NASDAQ: AZN), along with a resurgence of stock market indices like the Dow Jones Industrial Average and S&P 500, hints at a relatively stable...

After initial hiccups such as a tough FDA panel briefing document and a not-so-favorable panel verdict, Karyopharm Therapeutics Inc (NASDAQ: KPTI) managed to secure approval for its multiple myeloma treatment Xpovio three days ahead of the given PDUFA date. The Analyst H.C. Wainwright analyst...

Karyopharm Therapeutics Inc (NASDAQ: KPTI) shares, which suffered a setback in late February following the release of the FDA's briefing document and panel vote on its multiple myeloma treatment candidate Selinexor, were seeing upward momentum on double their average volume Friday. What...

La Jolla Pharmaceutical Company (NASDAQ: LJPC) reported net 2018 sales of $10.1 million for the septic shock treatment Giapreza this week and announced 2019 sales guidance of $24 million to $28 million for the drug.  The guidance represents continued linear growth, despite the company...

G1 Therapeutics Inc (NASDAQ: GTHX) reported positive top-line results Wednesday for its Phase 2 trilaciclib trial in small cell lung cancer. What Happened The candidate met primary endpoints in reducing the occurrence and duration of severe neutropenia. Compared to the placebo, it also allowed...

CELYAD SA/ADR (NASDAQ: CYAD) bolstered its entirely bullish cohort of analysts Monday with a fresh buyer. The Rating HC Wainwright analyst Edward White initiated coverage of Celyad with a Buy rating and $45 price target. The Thesis The chimeric antigen receptor therapy, or CAR-T,  ...

G1 Therapeutics Inc (NASDAQ: GTHX), a clinical-stage biopharmaceutical company that focuses on novel oncology therapeutics, boasts three drug candidates that address "potential blockbuster" markets, according to H.C. Wainwright. The Analyst H.C. Wainwright's Edward White initiated...

La Jolla Pharmaceutical Company (NASDAQ: LJPC) has an upcoming catalyst in the form of a Feb. 28 PDUFA date. An analyst at H.C. Wainwright recommends buying of the shares ahead of the decision.  The Analyst H.C. Wainwright analyst Edward White initiated coverage of the shares of La Jolla...

Shares of TESARO Inc (NASDAQ: TSRO) were trading higher by nearly 2 percent early Thursday morning after the U.S. Food and Drug Administration granted approval to the company's intravenous version of its therapy to treat nausea and vomiting in adults undergoing chemotherapy. An oral version of the...

H.C. Wainwright has initiated bullish coverage of four healthcare stocks headed into the end of 2017. Analyst Edward White explained his positive take on the four stocks in a research note on Thursday. Here’s a rundown of what he had to say. Acceleron Pharma - Buy White said the future of...